Sam Brusco, Associate Editor03.19.24
QT Imaging Holdings, a company focused on research, development, and commercialization of body imaging systems using low-frequency sound waves, has named Dr. Raluca Dinu as active CEO and a member of the company’s board. Dr. Dinu took office on March 12.
Dr. Dinu will serve in the position for one year, after which the company will reevaluate the strategic position. Dr. John Klock has stepped down as CEO, but will remain on the company’s board and transition to a company advisor.
Anastas (Stas) Budagov will take the role of chief financial officer. Budagov has been a contracting CFO with QT Imaging since December 2023 and accepted a permanent, full-time job with the company.
Dr. Dinu was previously CEO of GigCapital5 and has served as a senior executive in small and large companies. Dr. Dinu is on the board of many public traded companies and philanthropic organizations, and has co-founded five Private-to-Public Equity (PPE) companies.
“Raluca has an impressive record of turnaround, global operations, and public company governance. She has extensive M&A experience, deep product experience in regulated and unregulated industries, and has implemented innovative and collaborative workplace environments. QTI is playing a vital role in the development of advanced, accurate, non-invasive body scanning technology, and with Raluca at the helm, the company will transition to a solid public company, technology-led, leader in medical imaging,” said Dr. Avi Katz, chairman of the QT Imaging Holdings board.
In 2022, the company gained U.S. Food and Drug Administration (FDA) 510(k) clearance for its QTScan tool to calculate the breast’s fibroglandular volume (FGV) and ratio of FGV to total breast volume.
Dr. Dinu will serve in the position for one year, after which the company will reevaluate the strategic position. Dr. John Klock has stepped down as CEO, but will remain on the company’s board and transition to a company advisor.
Anastas (Stas) Budagov will take the role of chief financial officer. Budagov has been a contracting CFO with QT Imaging since December 2023 and accepted a permanent, full-time job with the company.
Dr. Dinu was previously CEO of GigCapital5 and has served as a senior executive in small and large companies. Dr. Dinu is on the board of many public traded companies and philanthropic organizations, and has co-founded five Private-to-Public Equity (PPE) companies.
“Raluca has an impressive record of turnaround, global operations, and public company governance. She has extensive M&A experience, deep product experience in regulated and unregulated industries, and has implemented innovative and collaborative workplace environments. QTI is playing a vital role in the development of advanced, accurate, non-invasive body scanning technology, and with Raluca at the helm, the company will transition to a solid public company, technology-led, leader in medical imaging,” said Dr. Avi Katz, chairman of the QT Imaging Holdings board.
In 2022, the company gained U.S. Food and Drug Administration (FDA) 510(k) clearance for its QTScan tool to calculate the breast’s fibroglandular volume (FGV) and ratio of FGV to total breast volume.